# Post Marketing Surveillance (PMS) Study to Assess Safety and Efficacy of Micardis in Patients With Essential Hypertension

> **NCT02245464** · — · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 13066 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** Telmisartan

## Key facts

- **NCT ID:** NCT02245464
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2000-11
- **Primary completion:** 2006-11
- **Final completion:** —
- **Target enrollment:** 13066 (ACTUAL)
- **Last updated:** 2014-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02245464

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02245464, "Post Marketing Surveillance (PMS) Study to Assess Safety and Efficacy of Micardis in Patients With Essential Hypertension". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02245464. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*